Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Clinical vertebral fractures · postmenopausal women with a higher risk for fracturesa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 1.07 [0.72, 1.58]
Studies not reported
Low
Hip Fracture · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.93 [0.17, 5.19]
Studies not reported
Very low
Woman's perception of pain (as defined by trialists) · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications associated with varicose veins and leg oedema (venous leg ulcer) · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms associated with varicose veins and oedema · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in event‐free survival compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in hypersensitivity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower pancreatitis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in thromboembolism compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in osteonecrosis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower asparaginase‐associated toxicity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Kidney recovery functionby KRT: continuous and intermittent KRT · AKI
Subgroup analyses: early showed no clear difference in kidney recovery functionby KRT: continuous and intermittent KRT compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
1 finding from 1 review
Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Proportion of children achieving 14 consecutive dry nights by the end of treatment · children with nocturnal enuresis
It is very uncertain whether alarm changes proportion of children achieving 14 consecutive dry nights by the… compared with other types of alarm (very low certainty).
1 finding from 1 review
Failure of treatment ‐ death or intermittent positive‐pressure ventilation (IPPV) before hospital discharge · preterm infants with respiratory distress for initial respiratory support
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intermittent and absolute claudication distances · people with critical limb ischaemia due to non‐reconstructable peripheral arterial disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: intermittent facial skin rash · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: intermittent facial skin rash compared with placebo (very low certainty).
1 finding from 1 review